PE20191818A1 - Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol - Google Patents
Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3olInfo
- Publication number
- PE20191818A1 PE20191818A1 PE2019002024A PE2019002024A PE20191818A1 PE 20191818 A1 PE20191818 A1 PE 20191818A1 PE 2019002024 A PE2019002024 A PE 2019002024A PE 2019002024 A PE2019002024 A PE 2019002024A PE 20191818 A1 PE20191818 A1 PE 20191818A1
- Authority
- PE
- Peru
- Prior art keywords
- iodophenyl
- azetidin
- difluoro
- fluoro
- carbonyl
- Prior art date
Links
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 title 1
- -1 {3,4-DIFLUORO-2 - [(2-FLUORO-4-IODOPHENYL) AMINO] PHENYL} CARBONYL Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 abstract 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713104P | 2012-10-12 | 2012-10-12 | |
| PCT/US2013/064866 WO2014059422A1 (en) | 2012-10-12 | 2013-10-14 | Novel process for making compounds for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191818A1 true PE20191818A1 (es) | 2019-12-27 |
Family
ID=49474740
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002024A PE20191818A1 (es) | 2012-10-12 | 2013-10-14 | Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol |
| PE2015000485A PE20151494A1 (es) | 2012-10-12 | 2013-10-14 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
| PE2019001563A PE20200387A1 (es) | 2012-10-12 | 2019-08-08 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000485A PE20151494A1 (es) | 2012-10-12 | 2013-10-14 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
| PE2019001563A PE20200387A1 (es) | 2012-10-12 | 2019-08-08 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9771347B2 (enExample) |
| EP (1) | EP2909188B1 (enExample) |
| JP (2) | JP6300042B2 (enExample) |
| KR (1) | KR102204520B1 (enExample) |
| CN (2) | CN108948043B (enExample) |
| AU (1) | AU2013328929B2 (enExample) |
| BR (1) | BR112015008113B1 (enExample) |
| CA (1) | CA2889466C (enExample) |
| CL (1) | CL2015000926A1 (enExample) |
| CR (2) | CR20200237A (enExample) |
| EA (1) | EA030613B1 (enExample) |
| ES (1) | ES2671502T3 (enExample) |
| GE (1) | GEP201706690B (enExample) |
| HK (1) | HK1213567A1 (enExample) |
| HR (1) | HRP20180670T1 (enExample) |
| IL (1) | IL238116B (enExample) |
| IN (1) | IN2015DN03928A (enExample) |
| MA (1) | MA38085B1 (enExample) |
| MX (2) | MX372708B (enExample) |
| MY (1) | MY186549A (enExample) |
| NZ (1) | NZ706723A (enExample) |
| PE (3) | PE20191818A1 (enExample) |
| PH (1) | PH12015500785A1 (enExample) |
| PL (1) | PL2909188T3 (enExample) |
| SA (1) | SA515360271B1 (enExample) |
| SG (1) | SG11201502795VA (enExample) |
| SI (1) | SI2909188T1 (enExample) |
| TR (1) | TR201807861T4 (enExample) |
| UA (1) | UA115455C2 (enExample) |
| WO (1) | WO2014059422A1 (enExample) |
| ZA (1) | ZA201502349B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201502795VA (en) | 2012-10-12 | 2015-05-28 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| CN108135854B (zh) | 2015-06-30 | 2022-03-11 | 基因泰克公司 | 含有药物的立即释放片剂和用于形成片剂的方法 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
| AU2017311585A1 (en) | 2016-08-12 | 2019-02-28 | Genentech, Inc. | Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor |
| WO2018064299A1 (en) | 2016-09-29 | 2018-04-05 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| KR20230156731A (ko) | 2021-03-09 | 2023-11-14 | 제넨테크, 인크. | 뇌암 치료에 이용하기 위한 벨바라페닙 |
| KR20230165795A (ko) | 2021-04-06 | 2023-12-05 | 제넨테크, 인크. | 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1563587A (en) * | 1924-09-20 | 1925-12-01 | Raney Murray | Method of preparing catalytic material |
| US1628190A (en) * | 1926-05-14 | 1927-05-10 | Raney Murray | Method of producing finely-divided nickel |
| US1915473A (en) * | 1930-12-31 | 1933-06-27 | Raney Murray | Method of preparing catalytic material |
| US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| BR9507203A (pt) | 1994-04-01 | 1997-09-09 | Shionogi & Co | Derivado de oxima e bactericida que contém o mesmo como ingredientes ativo |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6251943B1 (en) | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| CA2290509A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| CN1163475C (zh) | 1997-07-01 | 2004-08-25 | 沃尼尔·朗伯公司 | 4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途 |
| US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
| EP1140046A1 (en) | 1998-12-15 | 2001-10-10 | Warner-Lambert Company | Use of a mek inhibitor for preventing transplant rejection |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| HRP20010473A2 (en) | 1998-12-22 | 2002-08-31 | Warner Lambert Co | Combination chemotherapy |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| CA2350234A1 (en) | 1999-01-07 | 2000-07-13 | Alexander James Bridges | Treatment of asthma with mek inhibitors |
| CA2358438A1 (en) | 1999-01-07 | 2000-07-13 | David Thomas Dudley | Antiviral method using mek inhibitors |
| IL144215A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | 1-heterocycle substituted diarylamines |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| EP1144385B1 (en) | 1999-01-13 | 2005-08-17 | Warner-Lambert Company Llc | Benzoheterocycles and their use as mek inhibitors |
| JP2002534498A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤としてのベンゼンスルホンアミド誘導体およびその使用 |
| WO2001005390A2 (en) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| DE60005688T2 (de) | 1999-07-16 | 2004-04-29 | Warner-Lambert Co. Llc | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer |
| TR200200204T2 (tr) | 1999-07-16 | 2002-11-21 | Warner-Lambert Company | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi. |
| CN1373660A (zh) | 1999-07-16 | 2002-10-09 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| AU780787B2 (en) | 1999-09-17 | 2005-04-14 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| JP3811775B2 (ja) | 2000-07-19 | 2006-08-23 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル |
| YU14303A (sh) * | 2000-08-25 | 2006-08-17 | Warner Lambert Company Llc. | Postupak pripremanja n-aril antranilnih kiselina i njihovih derivata |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
| US7085492B2 (en) | 2001-08-27 | 2006-08-01 | Ibsen Photonics A/S | Wavelength division multiplexed device |
| CA2460118A1 (en) | 2001-10-31 | 2003-05-08 | Pfizer Products Inc. | Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome |
| DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
| BR0307060A (pt) | 2002-01-23 | 2004-10-26 | Warner Lambert Co | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico |
| JP2005526076A (ja) | 2002-03-13 | 2005-09-02 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋ阻害剤としてのｎ３アルキル化ベンズイミダゾール誘導体 |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| ZA200407220B (en) | 2002-03-13 | 2007-05-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| EP1515727A4 (en) | 2002-06-11 | 2009-04-08 | Merck & Co Inc | (HALO-BENZO CARBONYL) HETEROBICYCLIC P38 KINASE INHIBITION |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| WO2004004644A2 (en) | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| JP4617299B2 (ja) | 2003-03-03 | 2011-01-19 | アレイ バイオファーマ、インコーポレイテッド | ｐ３８阻害剤及びその使用法 |
| JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| WO2004113347A1 (en) | 2003-06-20 | 2004-12-29 | Celltech R & D Limited | Thienopyridone derivatives as kinase inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| BRPI0412851A (pt) | 2003-07-24 | 2006-10-03 | Warner Lambert Co | benzamidazóis de n-metila-substituìdos |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| EP1674452A4 (en) | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
| EP1689233B1 (en) | 2003-11-19 | 2012-07-04 | Array Biopharma, Inc. | Bicyclic inhibitors of mek |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| ES2298840T3 (es) | 2003-12-08 | 2008-05-16 | F. Hoffmann-La Roche Ag | Derivados de tiazol. |
| TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| US7956191B2 (en) | 2004-10-20 | 2011-06-07 | Merck Serono Sa | 3-arylamino pyridine derivatives |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| CN103524392B (zh) | 2005-10-07 | 2018-06-01 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶 |
| EP2056829B9 (en) | 2006-08-16 | 2012-09-26 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| US7999006B2 (en) * | 2006-12-14 | 2011-08-16 | Exelixis, Inc. | Methods of using MEK inhibitors |
| SG11201502795VA (en) | 2012-10-12 | 2015-05-28 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
| US9765032B2 (en) | 2014-02-07 | 2017-09-19 | Sumitomo Chemical Company, Limited | Method for producing (R)-1,1,3-trimethyl-4-aminoindane |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2013
- 2013-10-14 SG SG11201502795VA patent/SG11201502795VA/en unknown
- 2013-10-14 HR HRP20180670TT patent/HRP20180670T1/hr unknown
- 2013-10-14 MX MX2015004660A patent/MX372708B/es active IP Right Grant
- 2013-10-14 CN CN201810758236.XA patent/CN108948043B/zh active Active
- 2013-10-14 AU AU2013328929A patent/AU2013328929B2/en active Active
- 2013-10-14 JP JP2015536988A patent/JP6300042B2/ja active Active
- 2013-10-14 BR BR112015008113-4A patent/BR112015008113B1/pt active IP Right Grant
- 2013-10-14 CR CR20200237A patent/CR20200237A/es unknown
- 2013-10-14 PL PL13780303T patent/PL2909188T3/pl unknown
- 2013-10-14 MY MYPI2015000897A patent/MY186549A/en unknown
- 2013-10-14 TR TR2018/07861T patent/TR201807861T4/tr unknown
- 2013-10-14 NZ NZ706723A patent/NZ706723A/en unknown
- 2013-10-14 PE PE2019002024A patent/PE20191818A1/es unknown
- 2013-10-14 UA UAA201504532A patent/UA115455C2/uk unknown
- 2013-10-14 CA CA2889466A patent/CA2889466C/en active Active
- 2013-10-14 GE GEAP201313824A patent/GEP201706690B/en unknown
- 2013-10-14 ES ES13780303.7T patent/ES2671502T3/es active Active
- 2013-10-14 KR KR1020157012066A patent/KR102204520B1/ko active Active
- 2013-10-14 IN IN3928DEN2015 patent/IN2015DN03928A/en unknown
- 2013-10-14 PE PE2015000485A patent/PE20151494A1/es active IP Right Grant
- 2013-10-14 HK HK16101572.6A patent/HK1213567A1/zh unknown
- 2013-10-14 EP EP13780303.7A patent/EP2909188B1/en active Active
- 2013-10-14 CN CN201380064338.7A patent/CN104837826B/zh active Active
- 2013-10-14 EA EA201590700A patent/EA030613B1/ru not_active IP Right Cessation
- 2013-10-14 WO PCT/US2013/064866 patent/WO2014059422A1/en not_active Ceased
- 2013-10-14 MA MA38085A patent/MA38085B1/fr unknown
- 2013-10-14 SI SI201331045T patent/SI2909188T1/en unknown
-
2015
- 2015-04-02 IL IL238116A patent/IL238116B/en active IP Right Grant
- 2015-04-08 PH PH12015500785A patent/PH12015500785A1/en unknown
- 2015-04-08 ZA ZA2015/02349A patent/ZA201502349B/en unknown
- 2015-04-10 MX MX2020005533A patent/MX2020005533A/es unknown
- 2015-04-12 SA SA515360271A patent/SA515360271B1/ar unknown
- 2015-04-13 US US14/684,826 patent/US9771347B2/en active Active
- 2015-04-13 CL CL2015000926A patent/CL2015000926A1/es unknown
- 2015-05-11 CR CR20150245A patent/CR20150245A/es unknown
-
2017
- 2017-08-25 US US15/686,333 patent/US10239858B2/en active Active
- 2017-12-06 JP JP2017234208A patent/JP2018052973A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,215 patent/US10793541B2/en active Active
- 2019-08-08 PE PE2019001563A patent/PE20200387A1/es unknown
-
2020
- 2020-08-26 US US17/003,570 patent/US11414396B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191818A1 (es) | Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| MX361499B (es) | Baricitinib deuterado. | |
| PH12015501316A1 (en) | Heterocyclic compound | |
| NZ710444A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| PE20150887A1 (es) | Compuestos de benceno sustituidos | |
| MY207356A (en) | Nrf2 regulators | |
| MY164776A (en) | Heterocyclic compound | |
| MY163187A (en) | Novel imidazo-oxazine compound or salt thereof | |
| IN2015DN00598A (enExample) | ||
| TN2014000095A1 (en) | Pharmaceutical compositions | |
| EA201590951A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| EA201590954A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| UY33557A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno | |
| EA201590949A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| IN2014DN07224A (enExample) | ||
| BR112015015368A2 (pt) | composições de absorventes de dejetos de animais revestidas debaixa densidade | |
| MX2014002832A (es) | Nuevas imidazol-aminas como moduladores de la actividad de cinasas. | |
| SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| NI201200195A (es) | Procedimiento de preparación de la sal de l - arginina de perindoprilo | |
| EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
| IN2014DN07954A (enExample) | ||
| IN2014DN07220A (enExample) |